Divine Aleru, Microbiome Signatures Research Coordinator

This study reveals that low fiber and magnesium intake—not overeating or inactivity—contribute significantly to insulin resistance and hyperandrogenism in COS, with strong implications for microbiome-linked interventions.

The study explores how alterations in gut bacteria, fungi, and serum metabolites are linked to polycystic ovary syndrome (COS), revealing potential diagnostic markers and the role of hyperandrogenemia in disease development.

This study reveals significant dysbiosis of gut microbiota in women with COS, particularly in obese individuals. The altered microbial composition correlates with metabolic and hormonal imbalances, offering potential therapeutic targets for improving COS-related conditions.

This study explores the gut microbiota in women with COS and dyslipidemia, revealing significant microbial imbalances associated with lipid metabolism and hormonal dysregulation, offering potential targets for future therapies.

This study shows that gut microbiota dysbiosis in COS correlates with altered serum metabolites, including elevated PCs and reduced citric acid. Roseburia and Prevotella_9 were linked to protective metabolic profiles, while Shigella was associated with inflammation and lipid imbalance.

This study demonstrates that gut dysbiosis in COS is not just correlative but causative. MT and Lactobacillus transplantation restored hormonal balance and ovarian morphology in COS rats, confirming gut microbiota as a viable therapeutic target.

This study reveals disrupted diurnal rhythms and significant dysbiosis in the salivary microbiota of COS patients, notably elevated Fusobacterium and reduced Actinobacteria. These oral microbial patterns may influence systemic metabolic and hormonal dysregulation.

This study reveals that women with COS have altered gut fungal communities, marked by enriched Saccharomyces and depleted Aspergillus. These shifts may contribute to inflammation, metabolic stress, and endocrine disruption, highlighting fungi as critical players in COS pathophysiology.

This review links COS to gut microbiota dysbiosis, showing how PS leakage, CFA deficiency, and altered bile acids contribute to insulin resistance and hyperandrogenism. Microbiome-based therapies, including probiotics, prebiotics, and L-22, show strong promise.

This review presents COS as a multisystem disorder driven by gut dysbiosis, neuroendocrine disruption, and adipose androgen synthesis. Targeting B. vulgatus, L-22, and KR1C3 may offer novel interventions.